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ORIGINAL ARTICLE
Clinical Efficacy and Safety of Naltrexone Combination 
Therapy in Older Patients with Severe Pruritus
Jungsoo Lee, Jung U Shin, Seongmin Noh, Chang Ook Park, Kwang Hoon Lee
Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Background: Severe pruritus is a challenging condition, and 
it is more difficult to deal with in older patients due to their 
limitations in taking oral medication because of underlying 
diseases, possible interaction with concurrent medications, 
and poor general condition. Objective: We evaluated the ef-
ficacy and safety of naltrexone (ReviaⓇ), an opioid antago-
nist, in elderly patients with severe pruritus that was not easi-
ly controlled with conventional antipruritics. Methods: 
Eighteen patients were enrolled, with a mean age of 73 years. 
They additionally received 50 mg of naltrexone per day for 
an average of 2 months. Results: Using the visual analogue 
scale, 13 (72.2%) of 18 patients showed a “much improved” 
condition, reporting more than a 50% decrease in pruritus 
intensity. Sixteen (88.9%) showed symptomatic improve-
ment, and only 2 (11.1%) had persistent pruritus. Five pa-
tients reported side effects including insomnia, fatigue, con-
stipation, and anorexia. However, reactions were either lim-
ited to the first 2 weeks or well managed. Conclusion: 
Naltrexone could be an effective and safe alternative treat-
ment option to control severe pruritus in older patients. (Ann 
Dermatol 28(2) 159∼163, 2016)
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INTRODUCTION
Pruritus is a challenging symptom associated with various 
skin disorders. The consequent loss of sleep, physical dis-
figurement and skin lesions can even result in impairment 
of health-related quality of life. Skin senescence associated 
with skin dryness during old age causes long-term pruritus. 
Severe pruritus remains a difficult condition to control de-
spite development in many treatment modalities. In addi-
tion, older patients have many limitations in using oral 
medication due to their underlying diseases and the possi-
ble interactions with the medications that they are already 
taking.
One of the main mediators that produce the itching sensa-
tion is histamine, which is induced by many other media-
tors, thus increasing histamine-induced pruritus. However, 
often, an antihistamine agent cannot effectively suppress 
all types of pruritus because some neuropeptides, pro-
teases, and cytokines induce pruritus through a hista-
mine-independent pathway.
The role of opiate receptors in the perception of pruritus is 
emphasized by the observation that opiate antagonists 
suppress pruritus of a different origin by modifying the 
neuronal sensation of itching1. 
This study was designed to evaluate the efficacy and safety 
of naltrexone in the treatment of severe pruritus resistant 
to antihistamine agents in older patients.
MATERIALS AND METHODS
Sixteen patients with antihistamine-resistant severe pruritus 
were enrolled (Table 1) in this observational study. 
Informed consent was obtained from all patients, and the 
protocols were approved by the institutional review board 
(IRB No. 4-2011-0423). To study the safety and efficacy in 
older people, only patients 65 years and older with severe 
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Table 1. Characteristics of patients who received naltrexone combination therapy for 2 months
Diagnosis
Age (yr)/ 
Sex
Underlying 
disease
VAS
(pre tx)
VAS
(post tx)
Other accompanying tx Side effect
Prurigo 70/F DM 7 0 Antihistamine, topical steroids -
70/M 9 3 Antihistamine, topical steroids -
67/F LC 8 3 Antihistamine, topical steroids Insomnia
70/M HTN 9 4 Antihistamine, topical steroids Fatigue
Cholestatic pruritus 78/M HTN 8 1 Antihistamine -
80/M DM, HTN 9 3 Antihistamine -
Uremic pruritus 66/F CRF, DM 10 3 Antihistamine -
78/F CRF 8 8 Antihistamine Anorexia
Pruritus of unknown origin 65/M 8 3 Antihistamine -
83/M DM, HTN 8 4 Antihistamine Insomnia
73/M HTN 7 4 Antihistamine -
Post-scabietic pruritus 82/F DM 8 1 Antihistamine, topical steroids -
Psoriasis 77/F DM, HTN 10 2 Antihistamine, topical steroids, topical calcipotriol -
Eczema senilis 74/M DM, HTN 9 1 Antihistamine, topical steroids -
67/M DM 8 1 Antihistamine, topical steroids -
76/F 8 3 Antihistamine, topical steroids Constipation
72/M HTN 7 6 Antihistamine, topical steroids -
Cutaneous lymphoma 66/M 8 1 Antihistamine -
VAS: visual analogue scale, tx: treatment, F: female, M: male, DM: diabetes mellitus, LC: liver cirrhosis, HTN: hypertension, CRF: chronic
renal failure, -: not detected.
Fig. 1. Antipruritic effect of naltrexone according to the improvement 
of visual analoge scale (VAS) score was observed in sixteen patients 
(p＜0.05).
pruritus (a visual analogue scale [VAS] score 7 or higher) 
could sign up for the study. In addition, as naltrexone is 
not the first-line treatment option for pruritus, patients with 
a symptom that has not been easily controlled with con-
ventional antipruritic medications were selected for this 
study. The mean age of the patients was 73 years (range, 
65 to 83 years), and the men-to-women ratio was 6:4. 
Patients received 50 mg of naltrexone per day (ReviaⓇ; 
Bristol-Myers Squibb, Mulgrave, VIC, Australia) for approx-
imately 2 months (average, 66.5 days), and were instructed 
to continue their previous therapies including systemic 
corticosteroids, phototherapies, extra antipruritics, topical 
corticosteroids, and emollients. Most of the patients were 
given naltrexone with antihistamines and topical agents. 
All the patients had persistent itching sensation, either gen-
eralized or localized, caused by prurigo nodularis, choles-
tatic pruritus due to cholestatic liver disease, uremic pruri-
tus, eczema senilis, and cutaneous lymphoma. Some of 
the patients had pruritus of unknown origin. Baseline labo-
ratory tests were performed on the first visit, including 
complete blood cell count and routine chemistry with liver 
function test. Efficacy was assessed with a VAS ranging 
from 0 (no pruritus) to 10 (the most intensive pruritus they 
can imagine)2 and scored at the beginning, after 2 weeks, 
and at the end of the 2-month naltrexone treatment. 
Additional evaluation was performed to check adverse 
drug effects. Statistical analysis was conducted through a 
paired t-test by using IBM Statistical Package for the Social 
Sciences Statistics ver. 21 (IBM Co., Armonk, NY, USA).
RESULTS
According to the VAS scores, 13 (72.2%) of 18 patients re-
ported a “much improved” condition, experiencing more 
than 50% reduction in pruritus intensity (Table 1, Fig. 1). 
Among them, 6 (33.3%) reported an almost complete 
elimination of pruritus, with a VAS score of 0 or 1. Sixteen 
(88.9%) of 18 patients showed symptomatic improve-
ment, and only 2 (11.1%) had persistent pruritus. The ini-
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tial mean VAS score was 8.28±0.89, and at the end of the 
second week, the mean VAS score significantly decreased 
to 3.72±1.49 (p＜0.05). Finally, at the end of 2 months, 
the mean VAS score was again significantly lower 
(2.83±1.98), compared with both the initial VAS score 
and the VAS score at the end of the second week (p
＜0.05). In terms of disease entities of pruritic skin dis-
orders, patients with prurigo nodularis, cholestatic pruritus 
due to liver disease, uremic pruritus, xerotic eczema, ec-
zema senilis, cutaneous lymphoma, and pruritus of un-
known origin appeared to respond well to naltrexone. 
However, there was no statistically significant difference 
in drug efficacy related to the cause of pruritus (p=0.507). 
The first relief from pruritus was observed within 2 weeks, 
and the therapeutic effect was maintained during the study 
in all the patients who responded to naltrexone. In 14 
(77.8%) patients, the first relief from pruritus was observed 
within a week. Five patients had side effects including in-
somnia (two patients), fatigue, constipation, and anorexia. 
Except for constipation, adverse reactions were restricted 
to the first 2 weeks, and constipation was well managed 
by laxatives. No patient exhibited any elevation in liver 
enzyme in the blood test or experienced deterioration of 
their underlying diseases.
DISCUSSION
Antihistamines are widely used to control pruritus, and 
they have been considered as the only antipruritic therapy 
that is available for various types of pruritus3. They are al-
so generally safe for older patients, without causing con-
siderable drug interactions. Many elderly patients benefit 
from antihistamines because they are usually already tak-
ing many other medications due to their underlying 
diseases. Yet, there are many pruritic conditions that can-
not be controlled by antihistamines alone. In addition, his-
tamine is not the sole cause of itching.
We used naltrexone (ReviaⓇ) as a second-line treatment 
option for older patients with severe pruritus that could 
not be controlled by other means. The result showed that 
naltrexone relieves pruritus from various skin diseases and 
even itchiness associated with an internal disease, without 
significant side effects in older patients. The symptom was 
significantly improved after 2 weeks of naltrexone 
treatment. The decrease in the VAS score at the end of 2 
months was less prominent when compared with the VAS 
score reduction in the first two weeks. And yet it was also 
statistically significant. In addition, the overall decline in 
the VAS score in terms of significant pruritus improvement 
was observed at the end of the study (p＜0.05). Side ef-
fects including insomnia, tiredness, and anorexia were 
limited to the first 2 weeks only, and constipation was 
managed with laxatives, revealing the safety of using nal-
trexone in older patients. Throughout the rest of the 
2-month naltrexone treatment, no additional side effects 
were reported. Nausea is one of the most common ad-
verse effects of naltrexone, and there was a report show-
ing that younger patients are more likely to experience 
nausea4. Interestingly, none of our older patients had 
nausea. In our study with older patients, adverse reactions 
were reported in 5 (27.8%) patients. Other literature re-
ported 11.1% to 38.5% of subjects with heterogeneous 
age and side effects reported throughout the treatment pe-
riod5-7. In comparison with current literatures, naltrexone 
did not show a significantly higher frequency of side ef-
fects in patients who are older than 65 years.
It has already been reported that endogenous or exogenous 
opioids can induce or intensify pruritus8-10. There is a gen-
eral agreement on the fact that opioids induce an analgesic 
effect often in combination with pruritus evocation. 
However, a recent study showed that a long-lasting mor-
phine-induced itch via μ-opioid receptor (MOR1) and 
morphine-induced analgesia occur independently, where-
as short-acting morphine-induced scratching was provoked 
via isoform D of MOR1, and they are located on different 
sets of neurons8. The mode of action in the provocation of 
itch differs between central and peripheral applications9-11.
Opioid agonists themselves do not cause local itching 
upon injection or intradermal application. The antipruritic 
effect of MOR1 antagonists showed a central effect, and 
the κ-opioid receptor agonists revealed an effect on the 
spinal cord level. Opioid peptides have been implicated 
as mediators of cholestatic pruritus or pruritus of chronic 
kidney disease12,13, and upregulation of MOR1 in atopic 
dermatitis has been reported as well14.
Several randomized controlled trials have reported sig-
nificant improvement in pruritus by using naltrexone in 
cholestatic pruritus, chronic urticaria, and atopic dermati-
tis5,15-18, and a comparative study showed the efficacy of 
naltrexone in uremic pruritus6. The mean age of patients 
ranged from 45.3 to 62.6 years, and the study of 
Malekzad et al.5 had the most heterogeneous patient age, 
ranging from 24 to 85 years.
The antipruritic effect of naltrexone, a MOR1 antagonist, 
can be explained by a neuronal mechanism13. Administration 
of MOR1 antagonists inhibits pruritus by reversing the ef-
fect of opioids. Both pain-transmitting and pruritoceptive 
dorsal horn neurons run parallel to each other in the dorsal 
horn of the spinal cord, connected by opioid-sensitive 
interneurons. Usually, opioids act on pain-transmitting 
neurons and interneurons, producing neuronal inactivity 
and analgesia. Thus, the inhibition of interneurons on the 
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pruriceptive neurons is repealed, clinically stimulating the 
itching sensation. Naltrexone inhibits the activation of 
MOR1 and suppresses itching.
Naltrexone is a synthetic congener of oxymorphone that 
blocks the effects of opioids twice as much as naloxone. 
Naltrexone displaces endorphins at the μ- and κ-re-
ceptors and exhibits minimal pharmacological activity. 
Additionally, naltrexone has great oral bioavailability and 
shows linear increase in the area under plasma concen-
tration-time curve19. It is only contraindicated in patients 
with acute hepatitis, liver failure, and severe liver in-
sufficiency and should not be used in children, pregnant, 
or breast-feeding women13. Moreover, it must not be given 
to persons with drug addiction or to patients who are tak-
ing opioid analgesics and opioid-containing medications. 
Naltrexone does not have abuse potential because it does 
not cause physical dependence. In addition, it appears to 
have a favorable risk-to-benefit ratio and is usually well 
tolerated. Common side effects of naltrexone include with-
drawal-like reactions; gastrointestinal effects including nau-
sea, vomiting, and diarrhea; cardiovascular effects includ-
ing dizziness; and neurologic effects including fatigue and 
headache7,15,16,19-21. However, they are generally limited to 
the first 2 weeks of treatment. As the effect of the drug usu-
ally manifests within 2 weeks, naltrexone could be chal-
lenged for the first 2 weeks and maintained on patients 
who respond to the medication.
The limitation of this study is the relatively small number 
of patients without an additional double-blind placebo 
group. Nevertheless, as it has already been proven that 
naltrexone could be an effective second-line option to 
treat pruritus, and as there has been no study on its use on 
older patients, we focused on the safety of using naltrex-
one for 2 months as well as on its efficacy in elderly 
patients.
In addition, old people tend to have more severe and 
long-standing pruritus than younger subjects due to con-
current xerosis and skin barrier impairment secondary to 
skin aging, making them harder to treat. The fact that older 
patients are vulnerable to pruritus emphasizes the value of 
efficacy of naltrexone in this study.
In conclusion, naltrexone should be considered a safe and 
effective alternative treatment for older patients with se-
vere pruritus.
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